These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 18809143)

  • 1. HPV Vaccines: today and in the Future.
    Moscicki AB
    J Adolesc Health; 2008 Oct; 43(4 Suppl):S26-40. PubMed ID: 18809143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
    Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
    Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
    Diaz M; Kim JJ; Albero G; de Sanjosé S; Clifford G; Bosch FX; Goldie SJ
    Br J Cancer; 2008 Jul; 99(2):230-8. PubMed ID: 18612311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vaccination perspective against human papillomavirus and consequences for the screening of uterine cervical neoplasm].
    Delvenne P
    Bull Mem Acad R Med Belg; 2007; 162(10-12):483-8; discussion 489-90. PubMed ID: 18557390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus vaccines: current status and future prospects.
    Garland SM; Smith JS
    Drugs; 2010 Jun; 70(9):1079-98. PubMed ID: 20518577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus vaccines versus cervical cancer screening.
    Stanley M
    Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):388-94. PubMed ID: 18538554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer.
    Dull PM; Achilles SL; Ahmed R; Barnabas RV; Campos NG; Chirgwin K; Cohen JA; de Sanjosé S; Doorbar J; Einstein MH; Emerson CI; Gottlieb SL; Hildesheim A; Qiao Y; Ruff P; Sampson JN; Sasieni P; Schiffman M; Shin H; Stanley MA; Trimble CL; Wentzensen N; Riemer AB; Schiller JT; Kreimer AR
    Vaccine; 2024 Nov; 42(25):126100. PubMed ID: 39004526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M
    Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
    Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-appropriate use of human papillomavirus vaccines in the U.S.
    Castle PE; Fetterman B; Akhtar I; Husain M; Gold MA; Guido R; Glass AG; Kinney W
    Gynecol Oncol; 2009 Aug; 114(2):365-9. PubMed ID: 19464729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV and cervical cancer: screening or vaccination?
    Bosch FX; Castellsagué X; de Sanjosé S
    Br J Cancer; 2008 Jan; 98(1):15-21. PubMed ID: 18182975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.
    Zhao S; Hu S; Xu X; Zhang X; Pan Q; Chen F; Zhao F
    BMC Infect Dis; 2020 Nov; 20(1):846. PubMed ID: 33198657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
    Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HPV immunization for the prevention of cervical cancer].
    Mougin C; Bourgault-Villada I; Coursaget P
    Presse Med; 2009 Dec; 38(12):1750-68. PubMed ID: 19765945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.
    Bhat P; Mattarollo SR; Gosmann C; Frazer IH; Leggatt GR
    Immunol Rev; 2011 Jan; 239(1):85-98. PubMed ID: 21198666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S; Gasparini R; Panatto D; Demarteau N
    Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.